SCHEMBL2247535

SCHEMBL2247535

CC(C)(Cc1ccccc1)N(C(=O)c1ccc(-c2ccc(F)c(F)c2)cc1)[C@@H](CCC(=O)O)C(N)=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 3/20 0.40
ADAMTS5 Q9UNA0 2/20 0.40
MMP2 P08253 2/20 0.40
MMP8 P22894 2/20 0.40
ACLY P53396 1/20 0.34
FFAR1 O14842 1/20 0.34
ADAMTS4 O75173 1/20 0.34
ERN1 O75460 2/20 0.33
PTPN1 P18031 1/20 0.33
MMP13 P45452 1/20 0.33
S1PR1 P21453 1/20 0.33
HPGDS O60760 1/20 0.32
ALDH1A1 P00352 2/20 0.32
MAPT P10636 2/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
GPR68 Q15743 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2248769 0.94 MMP12 (0.44) MMP12ADAMTS5MMP2MMP8PTPN1
SCHEMBL2249342 0.90 MMP12 (0.43) MMP12ADAMTS5MMP2MMP8ADAMTS4
SCHEMBL2247591 0.86 MMP12 (0.42) MMP12ADAMTS5MMP2MMP8FFAR1
SCHEMBL2249890 0.86 MMP12 (0.48) MMP12ADAMTS5MMP2MMP8FFAR1
SCHEMBL2248530 0.86 PDE4A (0.45) MAPTPDE4APDE4BPDE4CPDE4D
SCHEMBL2248055 0.85 MMP2 (0.42) MMP12ADAMTS5MMP2MMP8FFAR1
SCHEMBL2251275 0.85 MMP12 (0.40) MMP12ADAMTS5MMP2MMP8FFAR1
SCHEMBL2254232 0.85 MMP12 (0.47) MMP12ADAMTS5MMP2MMP8FFAR1
SCHEMBL2245097 0.85 KMT2A (0.37) MMP12ADAMTS5MMP2MMP8PTPN1
SCHEMBL2247681 0.85 MMP12 (0.45) MMP12ADAMTS5MMP2MMP8FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US claimed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US claimed
US-7998965-B2 Glutamate aggrecanase inhibitors WYETH LLC (US) 2011-08-16 US disclosed
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2010-01-14 US disclosed
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS ADAMTS5, ADAMTS1, ADAMTS7 MMP12 54/4885ADAMTS5 1/4885MMP2 49/4885
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 MMP12 54/4885ADAMTS5 1/4885MMP2 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.